Effect of Intraocular Lens (IOL) Centration and Tilt on Visual Performance With Clareon® Vivity® IOL Implantation

East Coast Institute for Research

Status: Completed

Conditions: Cataract; Lenses, Intraocular

Treatments: Other: No intervention

Study type: Observational

Funder types: NETWORK; Industry; Other

Identifiers

NCT05827133

ECIR-Alcon-01

Details and patient eligibility

About

The goal of this observational study is to assess the effect of intraocular lens (IOL) movement in patients who have undergone Clareon® Vivity® IOL implantation.

The main question it aims to answer is: Does an association exist between IOL movement and patient quality of vision?

Participants implanted with Clareon® Vivity® and Vivity® Toric IOLs will be asked to do the following:

• consent to participate in the study
• allow researchers to access their personal medical records
• undergo a series of tests to assess the position of their IOLs and quality of vision

Researchers will assess participant examination results to determine whether an association exists between IOL movement and patient quality of vision.

Full description

This is a non-interventional, single-center, multi-surgeon, observational study to evaluate the effect of intraocular lens (IOL) centration and tilt on visual performance in patients who have undergone Clareon® Vivity® IOL implantation. The study population will include individuals implanted with Clareon® Vivity® and Vivity® Toric IOLs. IOL implantations reviewed will range from the earliest performed (May 2022) onward, until 100 implanted patients (200 eyes) are enrolled. Potential subjects will be consented, then retrospective chart review of pre-operative and operative implantation data will occur and postoperative data will be collected (1 or more months post-operation) via examination.

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• History of adult cataract and uneventful, refractive cataract surgery with Clareon® Vivity® or Vivity® Toric intraocular lens (IOL) implantation with manifest refraction spherical equivalent (MRSE) within ±1.00 D
• Willing to undergo an eye exam with pupil dilation

Exclusion criteria

• Moderate to severe posterior capsule opacification (2+ or more)
• Yttrium aluminum garnet (YAG) laser capsulotomy within 1 month prior to enrollment
• Laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) within the one year prior to IOL implantation or any time after IOL implantation
• Any previous ocular surgery (excluding YAG, LASIK, PRK)
• Clinically significant ocular pathology; severe diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, severe dry eye, irregular astigmatism, zonular weakness, pseudoexfoliation, ocular trauma
• Any additional procedure(s) at the same time as the Vivity implantation including but not limited to microinvasive glaucoma surgery (MIGS)
• Women who are pregnant at the time of screening (based on self-reported history)
• Medical or other problems which in the opinion of the investigator will render study participation unsafe

Trial design

101 participants in 1 patient group

Individuals implanted with Clareon® Vivity® or Vivity® Toric Intraocular Lenses (IOLs)

Treatment:

Other: No intervention